Sio Gene Therapies Inc.
Sio Gene Therapies Inc. (SIOX): 4 pipeline candidates · ~28 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
28.3 months
D/E 0.05 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Sio Gene Therapies Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$46.1M
Quarterly Burn
$4.9M
Runway
28.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| asp2957 | Phase 1/Phase 2 |
| axo-aav-gm1 | Phase 1/Phase 2 |
| axo-aav-gm2 | Phase 1/Phase 2 |
| axo-lenti-pd | Phase 2 |
Frequently asked questions
How many drug candidates are in Sio Gene Therapies Inc.'s pipeline?
Sio Gene Therapies Inc. (SIOX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sio Gene Therapies Inc.'s lead drug candidate?
Sio Gene Therapies Inc.'s most advanced tracked candidate is asp2957 (Phase 1/Phase 2) for X-Linked Myotubular Myopathy.
What is Sio Gene Therapies Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sio Gene Therapies Inc. has approximately 28.3 months of cash runway.
Get the full picture on Sio Gene Therapies Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.